What is Bicara Therapeutics's investing cash flow?

Bicara Therapeutics (BCAX) reported investing cash flow of $100.94M in Q1 2026.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Bicara Therapeutics BCAX Investing Cash Flow

Investing Cash Flow at other companies

Eli LillyLLY

-$3.92B-16.8%

AmgenAMGN

-$716M-60.2%

ArriVent BioPharma, Inc.AVBP

$3.58M-90.3%

ImmunomeIMNM

-$12.02M-336%

Arcus BiosciencesRCUS

$114M+256%

Syndax PharmaceuticalsSNDX

$38.39M-59.2%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's investing cash flow?: Bicara Therapeutics (BCAX) reported investing cash flow of $100.94M in Q1 2026.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.